CG Results Healthcare advises Charterhouse on its investment in Phastar
- Service: M&A
- Sector: Healthcare
- Sub Sector: CROs & CMOs
- Engagement Type: Buy Side
CG Results Healthcare is pleased to announce that it has advised Charterhouse Capital Partners, one of the longest established private equity firms in the UK, on its investment in PHASTAR, a specialist provider of biostatistics and data science services for clinical trials. Charterhouse is making its investment in partnership with the company’s founder, Kevin Kane, who remains CEO and retains a significant shareholding in the business alongside its management team.
This transaction highlights CG Results Healthcare’s capabilities in assisting private equity bidders to build a thesis and move at pace through a competitive process.
Founded in 2007, PHASTAR is a fast growing, specialist biometrics clinical research organisation (“CRO”) offering statistical consulting, clinical trial reporting, data science and data management services to a global customer base of large and mid-size pharmaceutical companies. Headquartered in London (UK) and North Carolina (US), the business operates across an international network of 12 offices. The business is focused on a highly attractive niche and is well-regarded by its customers for supporting them with their most critical and challenging data-related work.
We are pleased to have been supported by CG Results Healthcare on this transaction. Their sector knowledge and relationships were valuable, and put us in a great position to invest in this impressive business.
Partner, Charterhouse Capital Partners